Ophthalmic and mucosal preparations
OwnerEyal S. Ron, Dov Tamarkininventors
Life of this patent
Estimating the term…
Abstract
A composition to treat mucosal disorders includes a therapeutically effective quantity of an anti-TNF-α agent and a mucoadhessive delivery system.
Claims20
A composition to treat mucosal disorders comprising a therapeutically effective quantity of an anti-TNF-α agent and a mucoadhesive delivery system, wherein the anti-TNF-α agent comprises a TNF-α neutralizing agent.
A composition to treat mucosal disorders comprising a therapeutically effective quantity of an anti-TNF-α agent and a mucoadhesive delivery system, wherein the anti-TNF-α agent is a suppresser of the TNF-α signal transduction cascade.
A composition of to treat mucosal disorders comprising a therapeutically effective quantity of an anti-TNF-α agent and a mucoadhesive delivery system wherein the anti-TNF-α agent is a xanthine or a xanthine derivative.
A method of treating or preventing eye disorders, comprising topical application of a composition comprising a therapeutically effective quantity of an anti-TNF-α agent selected from a group consisting of TNF-α neutralizing agents suppressors of the TNF-α signal transduction cascade and xanthine or xanthine derivatives and a mucoadhesive delivery system onto the affected eye.
A method of treating or preventing oral cavity disorders, associated with elevated levels of pro-inflammatory cytokines, comprising topical application of a composition comprising a therapeutically effective quantity of an anti-TNF-α agent selected from a group consisting of TNF-α neutralizing agents, suppressors of the TNF-α signal transduction cascade, and xanthine or xanthine derivatives and a mucoadhesive delivery system onto the affected area.
A method of treating or preventing inflammatory and autoimmune disorders of the oral cavity, periodontitis, bacterial, fungal and viral infections, comprising topical application of a composition comprising a therapeutically effective quantity of an anti-TNF-α agent selected from a group consisting of TNF-α neutralizing agents, suppressors of the TNF-α signal transduction cascade, and xanthine or xanthine derivatives;
- and a mucoadhesive delivery system onto the affected area.
A method of treating or preventing aphthous ulcers, affecting mucous membranes of the mouth, lips, cheeks and gums of the oral cavity, comprising topical application of a composition comprising a therapeutically effective quantity of an anti-TNF-α agent selected from a group consisting of TNF-α neutralizing agents, suppressors of the TNF-α signal transduction cascade, and xanthine or xanthine derivatives;
- and a mucoadhesive delivery system onto the affected area.
Dependencies are inferred from the claim text.